Capital Digestive Care increases liver elastography volume by 171% with Velacur

FATTY LIVER DISEASE

Fatty liver disease is the fastest-growing segment of chronic liver disease, with an estimated one in three adults suffering from Metabolic Dysfunction-Associated Steatotic Liver Disease aka. MASLD (previously NAFLD) . In parallel, NALFD related mortality has been steadily increasing since the early 90s.

 

CAPITAL DIGESTIVE CARE

Case study site: Norfolk, VA
Providers on site: 9 Gastroenterologists
Capital Digestive Care is the largest gastroenterology group in the Mid-Atlantic states.

 

THE CHALLENGE

With early detection and intervention, fatty liver disease can be halted or even reversed. The recommended clinical guidance is to screen patients with FIB-4 followed by ultrasound-based elastography. As wait times for liver elastography procedures at Dr. Smith’s Capital Digestive Care (CDC) location began to extend into months, they needed to increase capacity to effectively screen and monitor patients for MASLD at the point of care. Their challenge was identifying and implementing a non-invasive point-of-care liver assessment device that would provide accurate, efficient measurements and maintain sustainable economics without disrupting the clinic’s workflow.

 

THE SOLUTION

AI guided ultrasound elastography device that measures liver stiffness and velacur determined fat fraction, the two key indicators of fatty liver disease, at the point of care. Velacur by Sonic Incytes offers providers:

    • Real-time results
    • Low up-front costs
    • AI guidance

 

PROJECT LEAD

Dr. John H. Smith is a board-certified, fellowship-trained gastroenterologist at Capital Digestive Care in Norfolk, Virginia. Dr. Smith has served as an assistant professor of internal medicine at Uniformed Services University of the Health Sciences. He was head of the gastroenterology and endoscopy department as well as assistant program director of the internal medicine residency program at the Naval Medical Center Portsmouth.

 

RESULTS
  • 90% of procedures successfully reimbursed through CPT code 76981
  • 9.7min average active scan time after initial learning curve
  • 171% increase in volume of liver elastography procedures

     

Read the Capital Digestive Care and Velacur case study here. 

Sync up

with Sonic

Be in-the-know on all our latest news!

Subscribe to our e-newsletter.

Julia PinterMarketing Director

Julia Pinter brings over a decade of medical technology marketing experience spanning product commercialization, launch strategy, and sales enablement. Prior to joining Sonic Incytes, she served as Director of Global GI Product Marketing at PENTAX Medical, where she led global downstream marketing for the company’s largest portfolio — driving commercial launches of next-generation endoscopes, imaging systems, and AI platforms across the Americas, Europe, and Asia-Pacific. At Sonic Incytes, Julia leads downstream marketing initiatives to expand awareness and accelerate adoption of Velacur One®, translating its clinical and economic value into programs that support broader adoption of non-invasive liver assessment.